Skip to content. | Skip to navigation

Personal tools

Navigation path

EURL ECVAM issues recommendation on three alternative-to-animal testing methods for carcinogenicity

News details
Mar 14, 2012

On 14 March 2012 the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) hosted by the European Commission's Joint Research Centre (JRC) issued a recommendation concerning three in vitro test methods for assessment of the carcinogenic potential of chemical substances. These test methods have the potential to reduce and replace testing on animals for safety assessment in the context of legislation on chemicals and cosmetics.

EURL ECVAM has conducted a study to assess the performance of three in vitro cell transformation assays (CTA) which model several stages of the cancer development process. The recommendation concludes these CTAs able to partially replace the currently used rodent carcinogenicity OECD Test Guidelines 451 and 453 which can lead to a significant reduction of laboratory animals and the time for toxicity testing needed.

The study results were peer reviewed by the EURL's Scientific Advisory Committee (ESAC), and the recommendation underwent public consultation.  The EURL ECVAM forwarded the results to the OECD for potential inclusion into the OECD Test Guidelines and subsequent international regulatory acceptance.

Background on EURL ECVAM:
The European Commission's Joint Research Centre (JRC) established the European Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) in 2010, as stipulated in Directive 2010/63 on the protection of animals used for scientific purposes. This European Union Reference Laboratory builds on the work and expertise of the European Centre for Validation of Alternative Methods (ECVAM), hosted by the JRC since 1991. The EURL ECVAM promotes and coordinates the development, validation, and use of standardised alternative methods to animal testing at EU and international level. It cooperates with EU Member States, stakeholders and validation bodies from the USA, Japan, Canada and South Korea.

More information: